Uncertainty is here to stay
Another turbulent year is ending, marked by economic, geopolitical, and technological shifts. With six decades behind me, I embrace this uncertainty as the norm. What does this mean for corporate decisions, especially in Pharma? I, [Ulrike Meier] with my colleague Eugenie Joanny, discussed the implications of a world of moving variables for the Deallus Pharma clients.
Uncertainty is inherent to most businesses, particularly in Pharma, where bench-to-bedside timelines can span a decade, and current decisions shape long-term success. Intensified uncertainty challenges our clients’ risk management and decision-making in a world where unpredictability and agility are the new normal.
We find three approaches instrumental in building robust assumptions for proactive, dynamic, and future-fit scenario planning:
Living in this dichotomy of uncertainty being a choice of good vs. bad might also reduce our cognitive burden as we are naturally wired to make quick judgements. When we are stuck in the dichotomy, however, we shield ourselves from learning. So while uncertainty is here to stay we are looking forward to 2025 and its opportunities to learn and continue to help clients adjust their sails, whatever the weather.
Authors – Ulrike Meier and Eugenie Joanny
December 2024